TG Therapeutics Inc Dossier
Qualitative Analysis
Business overview
TG Therapeutics, Inc. is a fully integrated, commercial-stage biotechnology company dedicated to the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company's primary commercial asset is BRIUMVI® (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) and several international regulatory bodies for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG Therapeutics is actively leveraging BRIUMVI as a 'pipeline-in-a-product' by expanding its clinical development into subcutaneous formulations and other autoimmune indications, alongside advancing azer-cel, an allogeneic CAR-T therapy.
Research as of 28 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the commercial adoption of BRIUMVI in the United States for relapsing forms of multiple sclerosis (RMS) by driving record new patient starts, expanding neurologist adoption, and leveraging high-efficacy clinical data.
Expected impact: Aims to drive full-year 2026 U.S. net product revenue to $885 million - $900 million and establish a durable, multi-billion-dollar long-term franchise.
Developing a self-administered, at-home subcutaneous formulation of ublituximab (BRIUMVI) to address the self-administered segment of the anti-CD20 market.
Expected impact: Expands the addressable market by capturing the estimated 35% of anti-CD20 patients who prefer self-administered therapies.
Advancing azercabtagene zapreleucel (azer-cel), an allogeneic (off-the-shelf) CD19 CAR-T cell therapy, into progressive forms of multiple sclerosis and other autoimmune indications.
Expected impact: Establishes a secondary high-potential therapeutic platform in neuroimmunology and autoimmune diseases beyond the core CD20 franchise.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Neuraxpharm holds exclusive rights to commercialize BRIUMVI in territories outside the United States, Canada, and Mexico (excluding certain previously partnered Asian countries). This partnership drives the global rollout of BRIUMVI, particularly in Europe, without requiring TG Therapeutics to build out its own international commercial infrastructure.
Terms: TG Therapeutics received a $140 million upfront payment, plus $12.5 million upon the first EU launch. The company is eligible for up to $492.5 million in additional launch and commercialization milestones, alongside tiered double-digit royalties on net sales reaching up to 30%.
Provides TG Therapeutics with exclusive worldwide rights to develop and commercialize the allogeneic CD19 CAR-T therapy, azercabtagene zapreleucel (azer-cel), for autoimmune diseases and other non-oncology indications, expanding its pipeline into cell therapy.
Terms: Precision BioSciences received $17.5 million in upfront and near-term milestones, with potential total deal value up to $288 million plus royalties. In March 2026, TG paid a $7.5 million clinical milestone (comprising $5.25 million cash and $2.25 million to purchase Precision common stock).